PT  - JOURNAL ARTICLE
AU  - ANA LAURA ORTEGA-GRANADOS
AU  - ÁNGEL ARTAL-CORTES
AU  - DAVID AGUIAR-BUJANDA
AU  - JUANA ORAMAS
AU  - JOSÉ LUIS FÍRVIDA
AU  - JAVIER DE CASTRO
AU  - JUANA CAMPILLO FUENTES
AU  - ROCÍO GORDO
AU  - RAQUEL GALÁN
AU  - JOSÉ TRIGO
AU  - on behalf of the ASPET Study Investigators
TI  - Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced <em>EGFR</em> Mutation-positive Non-small-cell Lung Cancer
AID  - 10.21873/anticanres.13244
DP  - 2019 Mar 01
TA  - Anticancer Research
PG  - 1317--1328
VI  - 39
IP  - 3
4099  - http://ar.iiarjournals.org/content/39/3/1317.short
4100  - http://ar.iiarjournals.org/content/39/3/1317.full
SO  - Anticancer Res2019 Mar 01; 39
AB  - Aim: To assess the patterns of disease progression in advanced/metastatic epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) on first-line treatment with erlotinib and identify potential prognostic factors for progression-free survival (PFS). Patients and Methods: Patients with stage IIIB/IV EGFR-mutation-positive NSCLC receiving first-line erlotinib were followed-up until 24 months after the last patient was enrolled or until premature withdrawal for any cause. Results: A total of 127 evaluable patients were enrolled. The median PFS and overall survival were 8.8 and 19.1 months, respectively. Disease progression was asymptomatic in 57.6% of patients and 53.3% developed new sites of metastasis. The presence of liver metastasis was identified as an independent prognostic factor for poor PFS. Conclusion: Metastatic progression with asymptomatic disease seems to be the predominant pattern of disease progression on first-line erlotinib in real-life practice in patients with advanced/metastatic EGFR-mutant NSCLC. Additionally, the presence of liver metastases may negatively affect PFS in these patients.